tion therapy was defined as an increase in left ventricular ejection fraction  $\geq 10$  % or a decrease in left ventricular end-systolic volume  $\geq 15$  % at the six months follow-up.

Non-responders to CRT

(n = 4, 13.8 %)

Responders to CRT

p-value

 $59.5 \pm 11.7$ 

 $43.0 \pm 1.8$ 

 $13.8 \pm 0.7$ 

 $6,996 \pm 1,275$ 

 $1.804 \pm 580$ 

A ga (vang)

RDW-SD (fl) RDW-CV (%)

WBC (106/L)

Lymphocytes (106/L)

Table 3: Baseline characteristics of the subgroup of ischemic cardiomyopathy patients. The response to cardiac resynchroniza-

rige (years)	$30.3 \pm 11.7$	$00.3 \pm 7.3$	0.27
Males	4 (100)	17 (68)	0.55
Laboratory parameters at ba	aseline		
Hemoglobin (g/dl)	$12.6 \pm 2.1$	$13.0 \pm 1.4$	0.70
Hematocrit (%)	$37.5 \pm 5.7$	$38.6 \pm 3.7$	0.74
Platelets (10 <sup>6</sup> /L)	$225,000 \pm 10,9839$	$224,800 \pm 52,339$	0.10

 $66.5 \pm 0.5$ 

 $44.6 \pm 4.6$ 

 $14.8 \pm 1.8$ 

 $7,478 \pm 1,963$ 

 $1.050 \pm 679$ 

0.27

0.24

0.07

0.54

0.66

Lymphocytes (10 /L)	1,004 ± 309	1,939 ± 070	0.00
Neutrophils (10 <sup>6</sup> /L)	$4,498 \pm 542$	$4,662 \pm 1,444$	0.69
NLR	$2.7 \pm 0.8$	$2.8 \pm 1.5$	0.88
PLR	$144.2 \pm 114.2$	$129.9 \pm 58.1$	0.82
PNR	$51.1 \pm 28.3$	$51.7 \pm 17.2$	0.97
LDH (U/L)	$285.3 \pm 134.7$	$224.9 \pm 52.5$	0.44
Continuous data are presented as mea	n values ± SD while categorical variables a	as absolute and relative frequencies (po	ercentages). LDH: lac-
tate dehydrogenase, NLR: neutrophil	to lymphocyte ratio, PLR: platelet to lympl	nocyte ratio, PNR: platelet to neutroph	il ratio, RDW-CV: red

blood cells distribution width-coefficient variation, RDW-SD: red blood cells distribution width-standard deviation, WBC: white blood cells.